Edison, NJ, United States of America

Mark A Laughlin

USPTO Granted Patents = 7 


Average Co-Inventor Count = 3.0

ph-index = 4

Forward Citations = 103(Granted Patents)


Location History:

  • Edison, NJ (US) (2002 - 2008)
  • Sandy, UT (US) (2012)

Company Filing History:


Years Active: 2002-2012

Loading Chart...
Loading Chart...
7 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Mark A. Laughlin

Introduction

Mark A. Laughlin is a notable inventor based in Edison, NJ, with a significant portfolio of seven patents. His work primarily focuses on the development of pharmaceutical compounds, particularly in the area of CCR5 antagonists.

Latest Patents

Among his latest patents is a groundbreaking invention involving Piperazine derivatives useful as CCR5 antagonists. This patent outlines the use of CCR5 antagonists of a specific formula or a pharmaceutically acceptable salt thereof, showcasing his innovative approach to addressing medical challenges.

Career Highlights

Mark A. Laughlin has made substantial contributions to the field of pharmaceuticals during his career at Schering Corporation. His expertise in medicinal chemistry and drug development has positioned him as a key player in the industry.

Collaborations

Throughout his career, Laughlin has collaborated with esteemed colleagues, including Bahige M. Baroudy and John W. Clader. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Mark A. Laughlin's contributions to the field of pharmaceuticals through his patents and collaborations highlight his role as a significant inventor. His work continues to impact the development of new therapeutic agents.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…